LifeStance Health Group, Inc.(LFST)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #630 of 2,962 stocksTOP 25%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
LFST Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for LifeStance Health Group, Inc. (LFST), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LFST at 63.4/100 on a 32-signal composite quality model, placing it at rank #630 of 2,962 stocks — the top 25% of the AI-ranked universe. LFST scores in the top quartile across earnings quality (93.7), revenue growth (77.3). Shareholder dilution risk is elevated at 24.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), LifeStance Health Group, Inc. reports quarterly revenue of $435.4M, net income of $23.6M, an operating margin of 7.0%. Top institutional holders of LFST by reported 13-F value include TPG GP A, FMR, BlackRock, based on the most recent SEC filings. LFST trades on the Nasdaq exchange and files with the SEC under CIK 1845257. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LFST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LifeStance Health Group, Inc. directly from SEC EDGAR. LifeStance Health Group, Inc.'s 13F Pro composite quality score has ranged between 36 and 63 since 2022, currently 63.4 — an improving long-term trajectory across 64 quarterly and live scoring snapshots.
Revenue
Q2 2026
$435.4M
Net Income
Q2 2026
$23.6M
Free Cash Flow
Q2 2026
$87.9M
Operating Margin
Q2 2026
7.0%
ROIC
Q2 2026
6.9%
D/E Ratio
Q2 2026
0.20
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+13.9% YoYNet Income
+116.8% YoYOperating Income
+176.4% YoYTotal Assets
+4.0% YoYTotal Debt
+0.0% YoYOp. Cash Flow
+36.3% YoYFree Cash Flow
+28.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.42B +13.9% | $1.25B +18.5% | $1.06B +22.8% | $859.5M +28.8% | $667.5M | — |
| Net Income | $9.7M +116.8% | $-57.4M +69.2% | $-186.3M +13.6% | $-215.6M +29.8% | $-307.2M | — |
| Operating Income | $24.1M +176.4% | $-31.6M +83.3% | $-189.1M +10.0% | $-210.2M +26.6% | $-286.4M | — |
| Total Assets | $2.20B +4.0% | $2.12B +0.4% | $2.11B -2.9% | $2.17B +12.8% | $1.93B +22.8% | $1.57B |
| Total Debt | $297.3M +0.0% | $297.3M +1.7% | $292.4M +23.7% | $236.3M +45.4% | $162.6M -56.9% | $377.6M |
| Operating Cash Flow | $146.2M +36.3% | $107.3M +735.3% | $-16.9M -132.0% | $52.8M +460.4% | $9.4M | — |
| Free Cash Flow | $110.0M +28.4% | $85.7M +249.3% | $-57.4M -116.9% | $-26.5M +68.9% | $-85.1M | — |
Get alerted when LFST's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for LifeStance Health Group, Inc. including:
Top Institutional Holders of LFST
TPG GP A, LLC
$1.2B111,744,614 shFMR LLC
$623.9M58,252,466 shBlackRock, Inc.
$389.3M36,348,507 shSUMMIT PARTNERS L P
$249.7M23,310,115 shVANGUARD PORTFOLIO MANAGEMENT LLC
$149.5M13,960,892 shJENNISON ASSOCIATES LLC
$129.4M12,077,557 shDIMENSIONAL FUND ADVISORS LP
$122.4M11,427,602 shVANGUARD CAPITAL MANAGEMENT LLC
$104.3M9,735,076 shSTATE STREET CORP
$88.1M8,228,351 shUBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME
$63.7M5,947,600 sh
| Fund | Value | Shares |
|---|---|---|
| TPG GP A, LLC | $1.2B | 111,744,614 |
| FMR LLC | $623.9M | 58,252,466 |
| BlackRock, Inc. | $389.3M | 36,348,507 |
| SUMMIT PARTNERS L P | $249.7M | 23,310,115 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $149.5M | 13,960,892 |
| JENNISON ASSOCIATES LLC | $129.4M | 12,077,557 |
| DIMENSIONAL FUND ADVISORS LP | $122.4M | 11,427,602 |
| VANGUARD CAPITAL MANAGEMENT LLC | $104.3M | 9,735,076 |
| STATE STREET CORP | $88.1M | 8,228,351 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME | $63.7M | 5,947,600 |
Companies Similar to LFST
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Alignment Healthcare, Inc.
REPLIGEN CORP
Envista Holdings Corp
Guardian Pharmacy Services, Inc.
AtriCure, Inc.
Arcutis Biotherapeutics, Inc.
Privia Health Group, Inc.
Progyny, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put LFST on your watchlist
Track score changes the day LifeStance Health Group, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is LFST a good stock to buy?
13F Pro's AI-powered analysis of LifeStance Health Group, Inc. (LFST) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LFST are available on the LFST stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. LFST is classified as a mid company.
Which hedge funds own LFST?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LFST. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of LifeStance Health Group, Inc.'s investment landscape.